SecBot SecBot
SECBOTREPLAY Home › Report › OCUL

OCUL · Ocular Therapeutix announced upcoming presentations of Phase 3 data for…

Ocular Therapeutix, Inc. · PRESS-RELEASE filed Apr 1, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Apr 1, 2026 at 07:00 ET

Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy AXPAXLI™ (OTX-TKI) in wet AMD at major ophthalmology conferences in April 2026. The data disclosures are part of ongoing scientific dissemination, not a regulatory approval or clinical trial result announcement.

  • Ocular Therapeutix will present SOL-1 Phase 3 data for AXPAXLI™ (OTX-TKI) in wet AMD at the Vit-Buckle Society meeting on April 11, 2026.
  • Additional presentations on diabetic retinal disease and wet AMD will occur at CNO 2026 in Buenos Aires from April 15–17, 2026.
  • AXPAXLI™ is an axitinib intravitreal hydrogel in Phase 3 trials for wet AMD and diabetic retinal disease, including NPDR.
  • No new clinical data, FDA decision, or commercial update was released, this is a schedule of upcoming scientific presentations.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access